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Summary We have previously demonstrated a 33% response rate in patients with primitive neurectodermal tumours after the direct injection
of 1311-monoclonal antibodies (MAbs) into the cerebrospinal fluid (CSF). Dose-limiting toxicity is myelosuppression due to the passage of the
radioimmunoconjugate from the CSF to the blood compartment. This occurs at doses of 2220 MBq of 131I-MAb and above, although this is not
seen in all patients studied and appears to be related to the degree of prior therapy received. Rather than attempting to improve the efficacy
of this approach to the treatment of disseminated disease within the CSF compartment by dose escalation and haemopoietic rescue, we have
explored the possibility of repeatedly administering the radioimmunoconjugate. Eight patients were recruited to the study, two of whom
received two and six of whom received three injections of 1311-MAb. After repeated administration of '311-MAb pharmacokinetic data revealed
that, with one exception, the radioimmunoconjugate cleared from the CSF compartment with similar kinetics, while its residence time in the
blood decreased with each injection. This was due to the development of an anti-mouse Ig response in the blood. Clearance of 131I-MAb from
the ventricular CSF appears to be independent of the presence of an anti-mouse Ig response in this compartment. The differential clearance
of the radioimmunoconjugate from the ventricular CSF and from the blood results in a marked increase in the therapeutic index that can
be achieved. Up to 5920 MBq of '311-MAb was administered as the third injection of radioimmunoconjugate and combined doses of up to
12 500 MBq were given without either haematological or neurological toxicity. These data illustrate that dose escalation and thus an increase
in the dose rate delivered to tumour cells within the CSF is possible if ways are found to reduce the residence time of the
radioimmunoconjugate in the blood compartment. Suggestions as to how this can best be achieved are reviewed in detail.
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Over the last decade it has become apparent that considerable prob-
lems exist in using monoclonal antibodies (MAbs) as delivery vehi-
cles for anti-cancer agents in patients. The extremely encouraging
responses seen in mice xenografted with human tumours have not
been translated into the clinic (Jones et al, 1985). Low levels of
antibody uptake into patient's solid tumour deposits have been
observed compared with those seen in animal studies (Esteban et al,
1987). In addition, there is marked heterogeneity in the distribution
of MAbs within solid tumours. These problems are thought to be
brought about by the relatively high interstitial pressure in tumours
compared with normal tissues, which limits the diffusion of large
molecules, such as immunoglobulins (Jain, 1988). A further
problem associated with the use of MAbs in patients compared
with animals is the difference in the volume of distribution of the
radioimmunoconjugate, potentially reducing the ability ofMAbs to
target to tumour. To attempt to overcome these problems several
groups have concentrated their efforts on administering antibodies
into body compartments that contain relatively small amounts of
diffuse tumour (Epenetos et al, 1987; Lashford et al, 1988).
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The cerebrospinal fluid (CSF) is conceptually ideal for targeting
studies as this exists within a closed compartment of approxi-
mately 125 cm3. It comprises the lateral cerebral ventricles, the
third and fourth ventricles and the sub-arachnoid space.
Cerebrospinal fluid is produced from the choroid plexus within the
ventricles and this flows into the sub-arachnoid space through
three foramina. CSF is produced at the rate of approximately
25 ml h-'. To maintain a constant volume it is absorbed primarily
through the arachnoid granulations, although it is also reported to
enter the lymphatics and leave the compartment through leakage
from the nerve roots.
We have previously reported a 33% response rate in patients
with disseminated primitive neuroectodermal tumours (PNET)
after a single bolus intraventricular injection of '311-MAbs into
their CSF, through an Ommaya reservoir (Coakham and
Kemshead, 1998). Patients were selected for study based upon
their having either diffuse disseminated disease and/or small
tumour nodules no larger than 1.5 cm in diameter, and no blockage
in their CSF pathways. As part ofthese Phase I studies, we identi-
fied the primary toxicity of this type of therapy as myelosuppres-
sion, which occurred idiosyncratically at doses of 2220 MBq of
'3'I-MAb and above (Papanastassiou et al, 1995). Pharmacokinetic
data indicate that myelosuppression is brought about through the
passage ofthe radioimmunoconjugate from the CSF into the blood
compartment. This clearly limits the possibility of increasing the
efficacy oftargeting by simple dose escalation.
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Table 1 Details of patients recruited to the study
Duration of
Patient Age Diagnosis MAb Number of treatment
(years) injections (months)
A 7 PNET (medulloblastoma) M340a 3 9
B 37 Carcinomatous meningitis (breast) HMFG1b 2 1
C 27 PNET (medulloblastoma) M340 3 5
D 3 Acute lymphoblastic leukaemia WCMHC 3 9
E 4 PNET (medulloblastoma) M340 2 3
F 43 PNET (medulloblastoma) M340 3 9
G 9 PNET (ependymoblastoma) M340 3 9
H 14 PNET (pineoblastoma) M340 3 3
aBourne et al (1989). bBurchell et al (1983). cPizer et al (1991).
Table 2 Area under the time activity curves for ventricular CSF and blood following repeated injection of radiolabelled MABs into patients with
disseminated disease in the CSF pathways
Patient Injection IA (MBq)a AUCVCSFb AUC AUCBLd AUCBLIAe AUCVCS/
VCSF/IAc AVCBL'
A 1 2026 NA - 15.99 7.8 x 10-3 NA
2 2267 294 0.12 1.58 6.9 x 10 4 186
3 2917 368 0.12 1.52 5.2 x 104 242
B 1 2959 363 0.12 15.5 5.2 x 10-3 23.4
2 4712 599 0.12 19.7 4.1 x 10-3 30.4
C 1 2856 211 0.07 15.7 5.4 x 10-3 13.4
2 3869 323 0.08 15.2 3.9 x 10-3 21.2
3 5362 432 0.08 10.3 1.9 x 10-3 41.9
D 1 2101 244 0.11 28.5 1.3 x 10-2 8.5
2 2236 227 0.10 2.96 1.3 x 10-3 76.6
3 3920 343 0.09 2.67 6.8 x 104 128.4
E 1 2205 212 0.09 37.2 1.6 x 10-2 5.6
2 3050 347 0.11 40.3 1.3 x 10-2 8.1
F 1 2380 230 0.09 18.4 8.5 x 10-3 12.5
2 2917 254 0.08 1.50 5.4 x 104 169.3
3 2553 269 0.11 1.88 7.3 x 10-4 196.2
G 1 2142 NA - NA - NA
2 2035 368 0.18 7.70 3.7 x 10-3 47.7
3 2460 433 0.18 5.14 2.0 x 10-3 84.2
H 1 2470 300 0.12 14.38 5.8 x 10-3 20.8
2 4446 376 0.09 4.63 1.0x 10-3 81.2
3 5920 400 0.07 4.92 5.5 x 104 81.3
alnjected activity into the ventricular CSF in MBq. bArea under the VCSF time activity curve MBq h ml-'. cArea under the VCSF time activity
curve/MBq administered MBq h ml-1. dArea under the blood time activity curve MBq h ml-1. eArea under the VCSF time activity curve/MBq
administered MBq h ml-'. 'Area under the VCSF time activity curve/area under the blood time activity curve.
To enhance the response of patients to targeted radiation
therapy, we have sought to administer repeated injections of
radioimmunoconjugate to a number of individuals with diffuse
malignant infiltrates within the CSF compartment. Pharmaco-
kinetic studies indicate that, in general, the clearance kinetics of
the radioimmunoconjugate from the ventricular CSF (VCSF)
remain constant throughout the course of antibody therapy. This
contrasts to the increasingly rapid removal of material from the
blood, brought about by the induction of an anti-mouse Ig
response. These findings have enabled us to escalate markedly the
amount of '3'I-MAb given to patients after their primary injection.
Within this context, no haematological or other toxicity was
encountered in patients receiving either a single intrathecal injec-
tion of up to 5920 MBq of '3'I-MAb or a cumulative dose of
radioimmunoconjugate in excess of 12 500 MBq given over a 3-
month period. Based upon this data, we propose that it should be
possible to overcome the primary toxicity of targeted radiation
therapy within the CSF compartment, and we review ways in
which this goal can be achieved.
MATERIALS AND METHODS
Patient recruitment
Ethical committee approval for this study was obtained from the
relevant committees at Frenchay Hospital and the Bristol Royal
Infirmary. Patients were recruited to the study after failure of
conventional treatment. All had diffuse leptomeningeal deposits
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without evidence of either solid parenchymal disease or spinal
block. Before treatment patients had an Ommaya reservoir
inserted into a lateral ventricle to facilitate the administration of
-311-MAbs and to allow ventricular CSF sampling.
Informed consent was obtained before the treatment and
patients were placed on a regimen to prevent free iodine accumu-
lation in the thyroid gland. Patients were also prescribed dexa-
methasone and phenytoin to reduce the risks of cerebral oedema
and fits respectively (Papanastassiou et al, 1995).
Monoclonal antibodies
Antibodies were chosen on the basis oftheir binding to either frozen
sections ofpatient's tumour or malignant cells within the CSF (Table
1). These reagents have also been screened extensively to demon-
strate that they do not cross-react with normal neural elements.
Monoclonal antibodies were conjugated to 'l3'I using the iodogen
technique to a specific activity of approximately 370 MBq mg-'
(Fraker and Speck, 1978). After radiolabelling, conjugates were
screened for the presence of free iodine by trichloroacetic acid
precipitation and fast protein liquid chromatography (FPLC), for the
presence of aggregates by FPLC and for immunoreactivity. In addi-
tion, samples were assayed for endotoxins (limulus test) and for
sterility. Radiolabelled MAbs were administered into the patient's
Ommaya reservoir as a bolus injection through a 0.22-ptm filter.
Radioimmunoconjugates were injected within 6 h of preparation to
avoid the possibility ofradiolysis.
It was our intention to administer three courses of radio-
immunotherapy to each patient, at approximately 4-week intervals.
For a variety of clinical and logistical reasons, this schedule was
not maintained. Brief details of the patients entered into the study
are presented in Table 1.
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Figure 1 Effective clearance of 131l-MAb from the ventricular CSF of patient
C. Samples were taken tram the Ommaya reservoir at different times and the
isotope levels determined in a LKB compugamma counter. U, Clearance
curve after the first injection of radioimmunoconjugate; 7,clearance curve
after the second injection of radioimmunoconjugate; A, clearance curve after
the third injection of radioimmunoconjugate
Patient sampling
Samples were taken at frequent intervals to determine the clear-
ance of radioimmunoconjugate from the blood and VCSF. These
were allowed to decay for a known period so that it was possible to
determine the level of radioactivity per unit volume in a LKB
Ultra-gamma counter. Knowing the efficiency of the counter, the
time of counting in relation to the time of immunoconjugate
administration and the decay constant ofthe isotope, the biological
and effective clearance curves for the isotope from VCSF and
blood could be calculated. The areas under the effective clearance
curves for VCSF and blood were determined from T( until the last
data point (approximately 168 h) by the linear-trapezoid rule. The
areas under the curves from the last data point to infinity were
calculated by integration. The total areas under these curves repre-
sent the time activity integrals for blood and CSF.
Dosimetry
To calculate the radiation dose to whole body, bone marrow, VCSF
and whole brain, the medical internal radiation dose (MIRD)
formalism was used (MIRD, 1971). A detailed description of the
methods used to determine the dose to these organs as a result of
intrathecal targeted radiation has been described previously
(Papanastassiou et al, 1995).
RESULTS
Patients and 1311-MAb administration
In total, eight patients were given repeated injections of '31I-MAbs,
two of these receiving two injections and the remainder three.
Patients received their targeted therapy over periods ranging from
1 to 9 months (Table 1). The six patients with PNETs received
multiple injections of radiolabelled MAb M340, while the other
two received either HMFG1 (patient B with carcinomatous menin-
gitis arising from a breast primary) or the anti-CD10 MAb WCMH
(patient D). Five ofthe eight patients were children (A, D, E, G, H)
and all ofthese presented with PNETs apart from D who was diag-
nosed with common acute lymphoblastic leukaemia (c-ALL).
Patients received between 2026 and 2959 MBq of '311-MAbs as
their initial injection, and this was dose escalated to a maximum of
5920 MBq (patient H, Table 2). The total amount ofradioimmuno-
conjugate given to patients ranged from 5255 to 12 836 MBq
(patients E and H respectively; Table 2).
In all instances the specific activity of the radioimmunoconju-
gate remained constant (approximately 10 ,uCi tga'). Preparations
contained less than 5% aggregates and 5% free iodine. The
immunoreactivity of the samples varied from 60% to 80%.
Toxicity
Acute
The acute toxicity observed in this study mirrored that previously
reported for patients receiving intrathecal targeted radiation
therapy (Papanastassiou et al, 1995). After the first injection of
radioimmunoconjugate, an acute aseptic meningitis was observed
in half of the patients (D, E, F, G) which resolved within 72 h.
When these patients received their second and subsequent injec-
tions of 1311-MAb, a transient aseptic meningitis reoccurred. No
acute toxicity was observed in the other half of the group, apart
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from in patient B. In this individual, the second injection of '31'-
MAb caused an elevation of intracranial pressure, which was
controlled by aspiration and the use of intravenous mannitol.
Dose-limiting toxicity
World Health Organization (WHO) grade 3/4 myelosuppression
was observed in three of the eight patients. In patient A, this
occurred 3 weeks after the first injection of 2026 MBq of radio-
immunoconjugate. Subsequent injections of 2267 and 2917 MBq
of '3'I MAb did not cause detectable myelotoxicity. Patient D, who
was heavily pretreated with combination chemotherapy, continued
on systemic maintenance chemotherapy for c-ALL throughout his
course of targeted radiation therapy. Myelosuppression occurred as
a result of each injection of radioimmunoconjugate, this being
treated on each occasion with granulocyte-macrophage colony-
stimulating factor (GM-CSF). It is therefore not possible to
comment accurately on the degree of myelosuppression caused as a
consequence of the radiolabelled antibody. Patient E only received
two injections of 1311-M340, the second being given while she was
pancytopenic. During this period, she also received GM-CSF
The maximum single dose of 1311-M340 administered to patients
was 5920 MBq. This was given as the third course of therapy to
patient H. No neural or haemopoietic toxicity was encountered as
a result of this injection. Several other patients also received, as
either their second or third injections of '311-MAb, doses of
radioimmunoconjugate in excess of 3000 MBq, without either
haematological or neural toxicity. Analysis of the pharmacokinetic
data presented below illustrates the reasons underlying the lack of
myelotoxicity and suggests that considerable dose escalation is
possible.
Pharmacokinetics
Over a period of 7 days, samples of ventricular CSF and blood
were taken from all of the patients. Wherever possible at least four
samples were acquired within the first 24 h, two within the second
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Figure 2 Effective clearance of 13l-MAb from the blood of patient C.
Samples (1-2 ml) were taken at different times and the isotope levels
determined in a LKB compugamma counter. U, Clearance curve after the
first injection of radioimmunoconjugate; Lii clearance curve after the second
injection of radioimmunoconjugate; A, clearance curve after the third
injection of radioimmunoconjugate
day after MAb administration and daily thereafter. From this data,
effective clearance curves were constructed for both ventricular
CSF and the blood. Figure 1 illustrates the data obtained from
patient C, expressed as the percentage of injected dose adminis-
tered. The VCSF clearance curves for this individual were typical
of the whole population studied. He received three injections of
'311-M340 of 2856, 3869 and 5362 MBq. Clearance of '311-MAb
from the VCSF followed biphasic clearance kinetics and remained
constant for all three injections of radioimmunoconjugate. In
contrast, the percentage of the injected dose of radioimmunocon-
jugate in the blood fell after each injection of radiolabelled MAb.
Peak blood levels reached 42%- at 32 h after the first injection of
radioimmunoconjugate, falling to just over 30% and 20% for the
second and third injections (Figure 2).
For patient C, the time activity integrals for the clearance
of '311-M340 from VCSF were calculated as 211, 323 and
432 MBq h mll for the three injections (Table 2). This increase
reflects the amount of radioimmunoconjugate administered, which
was almost doubled over the course of treatment. However, when
this data is normalized for the quantity of radioimmunoconjugate
administered, the time activity integral/unit injected activity remains
constant for each injection (0.07, 0.08 and 0.08 respectively).
A similar analysis of the blood clearance data for patient C
reveals time activity integrals of 15.7, 15.2 and 10.3 MBq h ml-'
for injections one, two and three. Thus, in contrast to the VCSF
data, the time activity integral for the radioimmunoconjugate in
the blood falls despite an increase in the amount of radionuclide
administered. This leads to a marked increase in the ratio of the
area under the VCSF-blood time activity curves (AUCVCSF/
AUCBlood). For patient C, this ratio rose from 13.4 after the first
injection of radioimmunoconjugate to 41.9 after the third injection
(Table 2).
It was not possible to obtain complete data sets for all eight
patients for logistical reasons. However, in all cases, apart from
patient H, the ratio of the area under the VCSF-blood time activity
curves increased after each injection of radioimmunoconjugate.
After the third injection of '3'I MAb to patient H, the ratio of
AUCVCSF/AUCBlood was found to be identical to that after the
second injection (Table 2). This was due to a marked increase in
the clearance rate of the '311-MAb from the VCSF of this patient
after his third injection of '311-MAb.
In four of the eight patients, the increase in the AUCVCSF/
AUCblood ratio was mainly brought about by a significant
decrease in the blood time activity integral after repeated injec-
tions of '311-MAb. In two of the other three (B and E), the time
activity integral in blood increased as the dose administered to the
VCSF was escalated. However, in these patients an increase in the
ratio between time activity integral in the VCSF-blood was still
observed, reflecting the differential clearance ofthe radioimmuno-
conjugate from the two body compartments. In the case ofpatients
A and G, full data were only available after the first injection of
'311-MAb, making a complete analysis impossible.
Anti-mouse Ig responses in blood and CSF
CSF and serum samples were acquired before the start ofthe study
from three patients (A, C and H). These were mixed in vitro with
'311-MAb to determine whether they affected the monomeric status
ofthe radiolabelled antibody. In all cases, FPLC analysis revealed
that the antibody alone resolved as a single band ofapproximately
150 kDa, and identical traces were obtained after preincubation of
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Figure 3 Fast protein liquid chromatography of 3I-MAb samples after mixing with either blood or CSF samples. (A) Serum and CSF samples taken from
patient C before the MAb study. (B) Serum and CSF samples taken from patient C before the third injection of MAb. (C) Serum and CSF samples taken from
patient A before the third injection of MAb. O, '3'1-MAb diluted in phosphate-buffered saline; ,'3'1-MAb mixed with serum; O, '3'1-MAb mixed with CSF
the reagent with either serum or CSF (Figure 3A). This study was
repeated with samples acquired before administration of the third
injection of radioimmunoconjugate. When these were mixed with
31I-MAb, radionuclide in the serum sample was associated with a
high-molecular-weight peak, indicating that the immunoglobulin
had aggregated, presumably as a result ofthe generation ofan anti-
mouse Ig response (Figure 3B). No aggregation of '31I-M340 was
seen in two of the three CSF samples taken before the third injec-
tion of radioimmunoconjugate (Patients C and H). In the other
VCSF sample from patient A, marked aggregation occurred
(Figure 3C). A semiquantitative radioimmune assay for the pres-
ence ofan anti-mouse Ig response in blood and CSF confirmed the
above findings, indicating that an anti-mouse Ig response was
detected in only the VCSF sample taken from patient A before his
third injection of radiolabelled MAb (data not presented).
Dosimetry
Repeated injections ofincreasing amounts of '311-MAbs resulted in
a marked rise in the calculated radiation dose to the VCSF, which
is representative of that received by free-floating tumour cells
within the fluid. For example, in patient C, the dose to the VCSF
increased from 26 Gy as a consequence of the first injection to
53 Gy after the third (Table 3). In contrast, the bone marrow dose
in this patient fell from 1.9 to 1.4 Gy. Considerably larger
decreases in the bone marrow dose were observed in other individ-
uals, ranging from three- to 20-fold. These occurred despite a
marked increase in radionuclide being administered to patients
(Tables 2 and 3). Whole-body doses remained low throughout the
study, these also falling as a consequence of the radioimmunocon-
jugate clearing with increasing rapidity from the blood. The dose
to whole brain remained acceptable throughout the study, ranging
from 0.24 to 0.68 Gy. The dose to this organ either remained
constant or fell slightly as the amount of radioimmunoconjugate
was increased throughout each patient's treatment.
Response
Because ofthe size ofthe group studied, it is clearly not possible to
determine whether repeating targeted radiation therapy in the CSF
compartment enhances the efficacy of treatment compared with
the results observed after a single bolus injection. However, for
completeness, the clinical outcome of the patients entered into the
study is documented.
In the PNET group, responses were observed in four of the six
individuals. Patient C remains alive and disease free 46 months
from the completion of treatment. A complete clearance of cells
from the CSF for 1 month after both the first and the second injec-
tions of '311-MAb was observed in patient E, who subsequently
deteriorated rapidly. Patient F had a complete response (CR) for 4
months after the first injection of radioimmunoconjugate. He was
then given two further injections 1 month apart and a complete
clearance of cells from the CSF was observed for a further 8
months. Finally, patient H received three injections of '31I-M340 at
monthly intervals. He had a complete response for 10 months
before rapidly relapsing with extensive disease. Patient A
remained with static disease for 12 months before relapse, and
patient G was not evaluable for response as he was treated after
surgery, in the adjuvant setting. He currently remains disease free
24 months from treatment.
Patient B with carcinomatous meningitis had a partial response
to antibody therapy, clearing cells from the CSF for periods of I
and 2 months after each injection of '3'I-MAb. She subsequently
relapsed and was considered too ill to receive further targeted
therapy. Patient D was not possible to evaluate for response as he
was also treated in the adjuvant setting. However, the period ofhis
third remission exceeded that of the second, suggesting that he
may have received some benefit from the radioimmunotherapy.
DISCUSSION
Previously, both our group and others identified the primary toxi-
city of intrathecal targeted radiation therapy as myelosuppression,
brought about by the clearance of the radiolabelled MAb from the
CSF compartment to the blood. Dose-limiting toxicity occurs at an
activity of approximately 2220 MBq of '311-MAb, although this
varies from patient to patient (Moseley et al, 1989; Bigner et al,
1995; Papanastassiou et al, 1995). The amount of combination
chemotherapy given to individuals before targeted radiation
therapy tends to render them more susceptible to myelosuppres-
sion. It is clearly possible to dose escalate above this toxicity,
through the use ofeither an autologous or allogeneic bone marrow
rescue procedure, as long as another toxicity does not immediately
become dose limiting. However, both of these techniques greatly
British Journal of Cancer (1998) 77(12), 2324-2330 . Cancer Research Campaign 19981311-labelledMAb treatment ofCNSmalignancies 2329
Table 3 Radiation dose (Gy) to whole body, bone marrow, ventricular CSF and brain following repeated injection of radiolabelled
MABs into patients with disseminated disease in the CSF pathways
Whole body Bone marrow VCSF Brain
Patient Injection Gy (Gy/IA)' Gy (Gy/IA) Gy (Gy/lA) Gy (Gy/IA)
A 1 0.17(8.3x10-5) 1.25(6.2x104) NA NA
2 0.02 (7.3x 104) 0.12 (5.4x 10-5) 36.3 (1.6x 10-2) 0.34 (1.5x 104)
3 0.02(5.4x104) 0.12(4.0x 1O-5) 43.1 (1.5x10-2) 0.43(1.5x 10-4)
B 1 0.18(6.2x 10-5) 1.37(4.6x10-4) 44.9(1.5x10-2) 0.41 (1.4x104)
2 0.24 (5.0 x 10-5) 1.74 (3.7 x 10-4) 74.1 (1.5 x 10-2) 0.68 (1.4 x 10-4)
C 1 0.29 (9.9 x 10-5) 2.2 (7.6 x 10-4) 26.1 (9 x 10-3) 0.24(8 x 10-5)
2 0.28 (7.2 x 10-5) 2.1 (5.3 x 10-4) 39.9 (1 x 10-2) 0.37 (9 x 10-5)
3 0.19(3.5x 10-5) 1.4(2.6x104) 53.4(1 x10-2) 0.49(9x 10-5)
D 1 0.16(7.6x 10-5) 1.18(5.6x 10-5) 30.1 (1.4x 10-2) 0.28 (1.4x104)
2 0.16 (7.3 x 10-5) 0.12 (5.3 x 10-5) 28.0 (1.2 x 10-2) 0.26 (1.2 x 10-4)
3 0.16(4.0x 10-5) 0.11 (2.8x 10-5) 38.5 (9.8x 10-3) 0.35 (9.0x 10-5)
E 1 0.14(6.3x 10-5) 1.03(4.6x10-4) 26.2(1.1 x10-2) 0.24(1.0x109)
2 0.15 (4.9 x 10-5) 1.12 (3.6 x 10-4) 42.9 (1.4 x 10-2) 0.39 (1.2 x 10-4)
F 1 0.32(1.3x104) 2.41 (1.0x 10-3) 28.4(1.2x10-2) 0.26(1.1 x104)
2 0.17(5.7x 10-5) 0.12(4.1 X10-5) 31.4(1.1 x10-2) 0.29(1.1 x104)
3 0.21 (8.2x 10-5) 0.15(5.8x 10-5) 33.2(1.3x10-2) 0.30(1.1 x10-4)
G 1 NA NA NA NA
2 0.17 (8.3 x 10-5) 1.27 (6.2 x 10-4) 45.5 (2.2 x 10-2) 0.42 (2.0 x 10-4)
3 0.14 (5.6 x 10-5) 1.04(4.2x 10-4) 48.6 (2.0 x 10-2) 0.45 (1.8 x10-4)
H 1 0.14(5.8x 10-5) 1.07(4.0x10-4) 37.1 (1.5x10-2) 0.34(1.3x104)
2 0.05 (1.0 x 10-5) 0.35 (7.8 x 10-5) 46.5 (1.0 x 10-2) 0.43 (9.6 x 10-5)
3 0.05 (8.7 x 10-6) 0.38 (6.4 x 10-5) 49.5 (8.3 x 10-3) 0.46 (7.7 x 10-5)
i,IA injected activity (MBq).
add to the complexity and cost of targeted therapy, a point of
particular concern when many of the patients are children.
As an alternative to dose escalation and haemopoietic rescue,
we have sought to demonstrate that we can conceptually improve
upon the efficacy of intrathecal '311-MAb treatment through the
repeated administration of a radioimmunoconjugate. This is not
ideal for basic radiobiological considerations, although the study
has led us to identify a way in which the primary toxicity of
myelosuppression can be simply overcome. Targeted radiation
therapy is very different from even hyperfractionated external
beam radiotherapy as it results in the delivery of continual low-
dose-rate radiation over a protracted period of time. Most radio-
biologists agree that this is not ideal as, if the dose rate is too low,
cells are capable of repairing the damage caused by the 3 emis-
sions from 1311. Repeated administration of '311-MAb therapy
simply prolongs the time cells are exposed to low-dose-rate radia-
tion; it does nothing to increase the dose rate. However, the effects
ofexposing cells to long periods oflow-dose-rate radiation are not
fully understood, and it is possible that, as a result of a repeated
radiation insult, they may lose their capacity to repair DNA.
Alternatively, increasing the dose rate delivered to tumour cells by
simple dose escalation theoretically offers a better approach to
enhancing radiation toxicity, if it were possible to overcome
myelotoxicity.
In this study, we have demonstrated that in seven of the eight
patients repeated injection of '311-MAb into the VCSF results in
identical clearance of the radioimmunoconjugate from this
compartment. In contrast, in all of the patients receiving three
injections of radiolabelled antibody, the conjugate cleared with
increasing rapidity from the blood. This results in maintaining the
dose to tumour cells within the VCSF, while reducing that to the
marrow compartment (Table 3). Dose escalation therefore
becomes possible without myelotoxicity, and we have demon-
strated this by increasing the amount of '3ll-MAb given to patients
from 2200 MBq to approximately 6000 MBq. No primary neural
toxicity was observed in individuals receiving this amount of
radioimmunoconjugate, suggesting that as long as ways are sought
to remove the radiolabelled antibody from the blood this degree of
dose escalation is safe and a further increase may be possible.
Several groups have demonstrated previously the potential
benefits that can result from using a 'clearing agent' such as an
anti-mouse Ig to remove MAbs from the blood (Marshall et al,
1994). Our concern regarding the application of this strategy to
patients receiving intrathecal targeted radiation therapy was that
an anti-mouse Ig would cross from the blood compartment to the
CSF, causing the radioimmunoconjugate to clear rapidly from this
compartment also. This study suggests that this phenomenon does
not occur. In one patient (A) an anti-mouse Ig response was
observed in both the blood and the VCSF after two intrathecal
injections ofmurine MAb. While the generation of an anti-mouse
Ig response resulted in the rapid clearance ofthe radioimmunocon-
jugate from the blood compartment, this was not the case for the
VCSF. Identical clearance kinetics were observed from the VCSF
irrespective of whether an anti-mouse Ig response was either
present or absent. It remains unclear as to whether this response
arose de novo within the CSF or whether it crossed from the blood
compartment.
Brightman (1969) and Cserr et al (1981) have reported that
clearance of macromolecules from the CSF to the blood occurs
through bulk flow. Both researchers found that a range of mole-
cules of differing sizes cleared from the CSF at similar rates. It is
therefore possible that aggregated and monomeric MAb will clear
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from the CSF compartment at the same rate, as appears to be the
case for patient A. Studies on guinea pigs have also confirmed that
IgG and IgM clear from the CSF ofanimals in an identical fashion
(B. Pizer, unpublished results).
The rapid clearance of '31l-MAb from the VCSF of patient H
after the third injection ofradioimmunoconjugate appears not to be
due to an anti-mouse Ig response in this compartment (Figure 3). It
is also likely that this is not due to factors such as the patient
having received either cranial spinal radiation and/or intrathecal
methotrexate as the phenomenon was not seen in other individuals
who had undergone these treatment modalities. It may be that the
enhanced clearance of macromolecules from the VCSF in patient
H on receiving a third injection of radioimmunoconjugate repre-
sents a toxicity ofthis particular type oftherapy that does not mani-
fest itself clinically. Further studies are warranted to address this
point and to substantiate the pharmacokinetic data reported above.
Our study on the repeated intrathecal administration of radio-
immunoconjugates to patients shows the benefits that can result,
with respect to enhancing the dose to tumour cells within the CSF.
It is anticipated that we could achieve our goal of giving a high
single injection of '311-MAb into the CSF compartment, without
toxicity if patients were initially immunized systemically with
mouse Ig to bring about the rapid clearance of the radioimmuno-
conjugate from this compartment. This approach may not be ideal
as it is well known that immune complex formation is involved in
a variety of pathologies. An alternative approach to clearing
radioimmunoconjugates rapidly from the blood is to use antibody
fragments (smaller than 60 kDa) to target radionuclides within the
CSF compartment. Assuming that these clear by bulk flow they
will have the same residence time in the CSF as whole antibody
and clear from the blood rapidly by glomerular filtration. Single-
chain Fv antibodies of approximately 30 kDa would be ideal for
such studies. The fact that these reagents will clear from the CSF at
the same rate as whole Ig remains to be tested, although we have
previously demonstrated that clearance rates are identical for both
whole Ig and (Fab), (JTK, unpublished observation). Enhanced
doses to kidney as a result of the rapid filtration of '311-scFv from
the blood should not be problematic as no nephrotoxicity has
resulted from administering high doses (<11 000 MBq) of the
small radiopharmaceutical meta-iodobenzylguanidine to tumours
in children with metastatic neuroblastoma (Voute et al, 1991).
Whatever the approach taken to increasing the therapeutic index
(dose to VCSF compared with that to blood and bone marrow) by
enhancing the clearance ofradioimmunoconjugate from the blood,
this study shows that a second toxicity will not be immediately
encountered. As discussed above, repeated injections over a period
of 3-9 months may not be the optimal way forward, but the data
presented illustrate how a very high dose of '311-MAb can be given
into the CSF as a single injection without bone marrow toxicity.
Further clinical studies are warranted in relapsed patients to prove
this hypothesis before introducing this approach to radiation
therapy into main line treatment.
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